Table 2 Clinical trials of CAR-NK cell-based cancer immunotherapy

1

Recruiting

Clinical Research of ROBO1 Specific CAR-NK Cells on Patients with Solid Tumors

Solid Tumor

Biological: ROBO1 CAR-NK cells

Phase 1, Phase 2

20

NCT03940820

May-2022

China

2

Unknown

Pilot Study of NKG2D-Ligand Targeted CAR-NK Cells in Patients with Metastatic Solid Tumours

Solid Tumor

Biological: CAR-NK cells targeting NKG2D ligands

Phase 1

30

NCT03415100

Dec-2019

China

3

Recruiting

Clinical Research of ROBO1 Specific BiCAR-NK/T Cells on Patients with Malignant Tumor

Malignant Tumor

Biological: BiCAR-NK/T cells (ROBO1 CAR-NK/T cells)

Phase 1, Phase 2

20

NCT03931720

May-2022

China

4

Not yet recruiting

Study of Anti-PSMA CAR NK Cell in Castration-Resistant Prostate Cancer

Castration-resistant Prostate Cancer

Biological: anti-PSMA CAR NK cells

Early Phase 1

9

NCT03692663

Dec-2021

5

Not yet recruiting

Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects with Recurrent/ Metastatic Gastric or Head and Neck Cancer

Gastroesophageal Junction (GEJ) Cancers; Advanced HNSCC

Drug: N-803; Drug: Pembrolizumab; Biological: PD-L1t-haNK

Phase 2

55

NCT04847466

Dec-2025

United States

6

Not yet recruiting

Study of Anti-Mesothelin Car NK Cells in Epithelial Ovarian Cancer

Epithelial Ovarian Cancer

Biological: anti-Mesothelin Car-NK cells

Early Phase 1

30

NCT03692637

Nov-2021

7

Recruiting

Clinical Research of ROBO1 Specific BiCAR-NK Cells on Patients with Pancreatic Cancer

Pancreatic Cancer

Biological: BiCAR-NK cells (ROBO1 CAR-NK cells)

Phase 1, Phase 2

9

NCT03941457

May-2022

China

8

Recruiting

NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers

Lymphoma, Non-Hodgkin;

B-cell Acute Lymphoblastic Leukemia;

Large B-cell Lymphoma

Biological: NKX019

Phase 1

60

NCT05020678

Jul-2038

United States; Australia

9

Recruiting

Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies

Acute Lymphocytic Leukemia; Chronic Lymphocytic Leukemia; Non-Hodgkin’s Lymphoma

Drug: Fludarabine; Cyclophosphamide; CAR-NK-CD19 cells

Phase 1

27

NCT04796675

Mar-2024

China

10

Recruiting

Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies

B-Lymphoid Malignancies; Acute Lymphocytic Leukemia; Chronic Lymphocytic Leukemia; Non-Hodgkin Lymphoma

Drug: Fludarabine; Drug: Cyclophosphamide; Drug: Mesna;

Phase 1, Phase 2

36

NCT03056339

Jun-2022

United States

11

Recruiting

Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19 + Relapsed/Refractory Hematological Malignancies

Acute Lymphoblastic Leukemia; Chronic Lymphoblastic Leukemia; B-cell Lymphoma

Drug: Fludarabine; Cyclophosphamide; CAR-NK-CD19 cells

Phase 1

27

NCT04796688

Mar-2024

China

Rank

Status

Study Title

Conditions

Interventions

Phase

Number Enrolled

NCT Number

Study Complete

Location

12

Not yet recruiting

Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma

Multiple Myeloma, Refractory

Biological: Anti-BCMA CAR-NK Cells; Drug: Fludarabine; Drug: Cytoxan

Early Phase 1

27

NCT05008536

Sep-2023

China

13

Recruiting

NKX101, Intravenous Allogeneic Engineered Natural Killer Cells, in Adults with AML or MDS

Relapsed/Refractory AML; AML, Adult MDS; Refractory Myelodysplastic Syndromes

Biological: NKX101 - CAR NK cell therapy

Phase 1

64

NCT04623944

Jul-2038

United States;

14

Not yet recruiting

Anti-CD33 CAR NK Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Leukemia, Myeloid, Acute

Biological: anti-CD33 CAR NK cells; Drug: Fludarabine; Drug: Cytoxan

Phase 1

27

NCT05008575

Sep-2023

China

15

Unknown

CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML

Acute Myelogenous Leukemia; Acute Myeloid Leukemia; Acute Myeloid Leukemia with Maturation

Biological: anti-CD33 CAR-NK cells

Phase 1, Phase 2

10

NCT02944162

Sep-2018

China

16

Recruiting

Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM

Multiple Myeloma

Biological: BCMA CAR-NK 92 cells

Phase 1, Phase 2

20

NCT03940833

May-2022

China

17

Not yet recruiting

Study of Anti-CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma

Refractory B-Cell Lymphoma

Biological: Anti-CD22 CAR NK Cells

Early Phase 1

9

NCT03692767

Nov-2021

18

Not yet recruiting

Study of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma

Refractory B-Cell Lymphoma

Biological: Anti-CD19 CAR NK Cells

Early Phase 1

9

NCT03690310

Nov-2021

19

Not yet recruiting

Anti-CD19 CAR NK Cell Therapy for R/R Non-Hodgkin Lymphoma.

NHL

Biological: anti-CD19 CAR NK

Early Phase 1

9

NCT04639739

Dec-2023

China

20

Recruiting

Clinical Study of HLA Haploidentical CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL

B-cell Non-Hodgkin Lymphoma

Biological: anti-CD19 CAR-NK

Phase 1

25

NCT04887012

May-2024

China

21

Unknown

Study of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma

Refractory B-Cell Lymphoma

Biological: Anti-CD19/CD22 CAR NK Cells

Early Phase 1

10

NCT03824964

Jan-2021

22

Unknown

PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients with CD19 Positive Leukemia and Lymphoma

Acute Lymphocytic Leukemia; Chronic Lymphocytic Leukemia; Follicular Lymphoma

Biological: anti-CD19 CAR-NK cells

Phase 1, Phase 2

10

NCT02892695

Sep-2019

China

23

Withdrawn

CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma

CD19 Positive Mantle Cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma

Procedure: Autologous Hematopoietic Stem Cell Transplantation; Drug: Carmustine; Drug: Cytarabine

Phase 1, Phase 2

0

NCT03579927

Oct-2019

United States